Ibrance is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Us Pharmaceuticals. The primary component is Palbociclib.
Product ID | 63539-284_3984414f-adad-4b6d-98f1-db4584562a0e |
NDC | 63539-284 |
Product Type | Human Prescription Drug |
Proprietary Name | Ibrance |
Generic Name | Palbociclib |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2020-03-30 |
Marketing Category | NDA / NDA |
Application Number | NDA212436 |
Labeler Name | US Pharmaceuticals |
Substance Name | PALBOCICLIB |
Active Ingredient Strength | 75 mg/1 |
Pharm Classes | Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2020-03-30 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA212436 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2020-03-30 |
Marketing Category | NDA |
Application Number | NDA212436 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2020-03-30 |
Ingredient | Strength |
---|---|
PALBOCICLIB | 75 mg/1 |
NDC | Brand Name | Generic Name |
---|---|---|
0069-0187 | Ibrance | palbociclib |
0069-0188 | Ibrance | palbociclib |
0069-0189 | Ibrance | palbociclib |
0069-0284 | Ibrance | palbociclib |
0069-0486 | Ibrance | palbociclib |
0069-0688 | Ibrance | palbociclib |
63539-187 | Ibrance | palbociclib |
63539-188 | Ibrance | palbociclib |
63539-189 | Ibrance | palbociclib |
63539-284 | Ibrance | palbociclib |
63539-486 | Ibrance | palbociclib |
63539-688 | Ibrance | palbociclib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
IBRANCE 86314613 4928206 Live/Registered |
Pfizer Inc. 2014-06-19 |
IBRANCE 85444239 4518147 Live/Registered |
Pfizer Inc. 2011-10-11 |
IBRANCE 77448185 not registered Dead/Abandoned |
Pfizer Inc. 2008-04-15 |